Abbott Laboratories (ABT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $186.10B
Last updated: Nov 17, 2026 at 4:42 PM ET
Abbott Laboratories (ABT) Statistics
Abbott Laboratories (ABT) has a market cap of $186.10B and an enterprise value of $213.20B. Its trailing P/E is 19.5x.
Total Valuation
Enterprise value is 14.57% above the market cap, as debt exceeds cash.
| Market Cap | $186.10B |
|---|---|
| Enterprise Value | $213.20B |
| Latest price (Nov 17, 2026) | $104.76 |
Key Dates
The next earnings report is expected on Jan 20, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 15, 2026.
| Next Earnings Date | Jan 20, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Last Ex-Dividend Date | Oct 15, 2026 |
| Last Payment Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.8x and 3.6x. Its year-end P/E ranged from 17.5x to 30.0x from 2016 to 2025.
| P/E Ratio | 19.5x |
|---|---|
| Forward P/E | 18.8x |
| P/S Ratio | 3.8x |
| Forward P/S | 3.7x |
| P/B Ratio | 3.6x |
| P/FCF Ratio | 26.9x |
| P/OCF Ratio | 21.0x |
| PEG Ratio | 2.1 |
Enterprise Valuation
Counting debt and cash, the company is valued at 18.7x EBITDA and 30.9x free cash flow.
| EV / Earnings | 45.4x |
|---|---|
| EV / Sales | 4.4x |
| EV / EBITDA | 18.7x |
| EV / EBIT | 29.3x |
| EV / FCF | 30.9x |
Price Statistics
The stock is down 19.37% over 52 weeks and trades 1.16% above its 50-day average.
| Beta (1Y) | 0.10 |
|---|---|
| 52-Week Change | -19.37% |
| 1-Month Change | +0.67% |
| 3-Month Change | -7.90% |
| 6-Month Change | +18.78% |
| 5-Year Change | -17.60% |
| 10-Year Change | +170.64% |
| Total Return (1Y) | -17.43% |
| Total Return (3Y CAGR) | +3.04% |
| Total Return (5Y CAGR) | -2.42% |
| Return vs SPY (1Y) | -30.56% |
| Max Drawdown (1Y) | -36.63% |
| Max Drawdown (3Y) | -40.73% |
| Sharpe Ratio (1Y) | -0.74 |
| Correlation with SPY (1Y) | 0.05 |
| 50-Day Average | $103.56 |
| 200-Day Average | $100.73 |
| 52-Week Range | $80.89 to $128.30 |
| RSI (14 Days) | 45.9 |
| Average Volume (20 Days) | 9.09M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.45x current liabilities, and total debt is 0.61x shareholder equity.
| Current Ratio | 1.45x |
|---|---|
| Quick Ratio | 1.00x |
| Debt / Equity | 0.61x |
| Debt / EBITDA | 2.79x |
| Debt / FCF | 4.61x |
| Interest Coverage | 7.30x |
Returns and Efficiency
Return on invested capital is 6.34% over the last 12 months, against a 5-year average of 12.11%.
| Return on Equity (ROE) | 9.21% |
|---|---|
| Return on Assets (ROA) | 4.34% |
| Return on Invested Capital (ROIC) | 6.34% |
| Return on Capital Employed (ROCE) | 7.89% |
| ROE (5Y Average) | 18.82% |
| ROA (5Y Average) | 10.10% |
| ROIC (5Y Average) | 12.11% |
| Asset Turnover | 0.50x |
| Inventory Turnover | 2.83x |
| Receivables Turnover | 5.47x |
| Cash Conversion Cycle | 112 days |
Taxes
Income tax took 28.36% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.86B |
|---|---|
| Effective Tax Rate | 28.36% |
Scores
ABT has an Altman Z-Score of 3.32, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.32 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $48.23B over the last 12 months is up 10.00% from the 12 months before.
| Revenue | $48.23B |
|---|---|
| Revenue Growth (YoY) | +10.00% |
| Gross Profit | $27.46B |
| Operating Income | $6.65B |
| Pretax Income | $6.56B |
| Net Income | $4.70B |
| EBITDA | $11.18B |
| EBIT | $7.27B |
| Reported EPS (TTM) | $5.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 47.14% of the $108.25B in total assets.
| Cash and Equivalents | $4.05B |
|---|---|
| Total Debt | $31.16B |
| Net Debt | $27.11B |
| Net Debt Per Share | $15.63 |
| Working Capital | $7.34B |
| Shareholder Equity | $51.03B |
| Book Value Per Share | $29.42 |
| Tangible Book Value | -$1.21B |
| Total Assets | $108.25B |
| Total Liabilities | $56.62B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.10B of capital spending, operating cash flow left $6.76B of free cash flow.
| Operating Cash Flow | $8.86B |
|---|---|
| Capital Expenditures | $2.10B |
| Free Cash Flow | $6.76B |
| FCF Per Share | $3.90 |
| Depreciation and Amortization | $3.91B |
| Dividends Paid | $4.32B |
| Share Repurchases | $1.54B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 13.78%, against a 5-year average of 17.86%.
| Gross Margin | 56.94% |
|---|---|
| Operating Margin | 13.78% |
| Pretax Margin | 13.61% |
| Net Margin | 9.75% |
| EBITDA Margin | 23.18% |
| EBIT Margin | 15.07% |
| FCF Margin | 14.01% |
| Gross Margin (5Y Average) | 56.03% |
| Operating Margin (5Y Average) | 17.86% |
| Net Margin (5Y Average) | 18.65% |
Growth
Revenue grew 0.51% a year over 3 years, and EPS fell 1.20% a year.
| Revenue Growth (3Y CAGR) | +0.51% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.08% |
| EPS Growth (3Y CAGR) | -1.20% |
| EPS Growth (5Y CAGR) | +7.13% |
| FCF Growth (3Y CAGR) | -1.78% |
| FCF Growth (5Y CAGR) | +5.26% |
| Operating Income Growth (3Y CAGR) | -1.25% |
| Book Value Per Share Growth (2Y CAGR) | +16.24% |
| Tangible Book Per Share Growth (2Y CAGR) | +92.26% |
Dividends and Yields
ABT pays out 49.36% of earnings as dividends.
| Dividend Per Share (Annual) | $2.52 |
|---|---|
| Dividend Yield | 2.41% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +7.87% |
| Dividend Growth (5Y CAGR) | +10.38% |
| Payout Ratio | 49.36% |
| FCF Payout Ratio | 63.99% |
| Earnings Yield | 5.13% |
| FCF Yield | 3.72% |
| Buyback Yield | 0.85% |
| Shareholder Yield | 3.23% |
Peer Position
Against 10 similar companies, ABT has the 6th highest P/E.
P/E RatioPeer median 18.8x
P/S RatioPeer median 3.9x
ROICPeer median 9.82%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.14%
Dividend YieldPeer median 0.57%
| P/E Ratio | 19.5x vs 18.8x median |
|---|---|
| P/S Ratio | 3.8x vs 3.9x median |
| ROIC | 6.34% vs 9.82% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.00% vs +8.14% median |
| Dividend Yield | 2.41% vs 0.57% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.86% and EPS growth at 7.37% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.86% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +7.37% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ABT
What is ABT's market cap?
Abbott Laboratories has a market cap of $186.10B. Its enterprise value, which adds debt and subtracts cash, is $213.20B.
What is ABT's P/E ratio?
Abbott Laboratories has a trailing P/E ratio of 19.5x and a forward P/E of 18.8x.
How many shares of ABT are outstanding?
Abbott Laboratories has 1.73B shares outstanding. The count is down 0.44% from a year earlier.
Does ABT pay a dividend?
Yes. Abbott Laboratories pays $2.52 a share a year, a dividend yield of 2.41%.
How much debt does ABT have?
Abbott Laboratories has $31.16B of total debt and $4.05B of cash and equivalents, a net debt position of $27.11B.
ABT pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts